| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jorge M A Oliveira | |
| P2860 | cites work | Tripartite synapses: astrocytes process and control synaptic information | Q22337308 |
| Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease | Q24621854 | ||
| Increased susceptibility of striatal mitochondria to calcium-induced permeability transition | Q28183063 | ||
| Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases | Q28269333 | ||
| Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease | Q28512442 | ||
| Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro | Q28584697 | ||
| Tripartite synapses: glia, the unacknowledged partner | Q29615224 | ||
| Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases | Q29615646 | ||
| N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking | Q30486372 | ||
| Effects of overexpression of huntingtin proteins on mitochondrial integrity | Q30489322 | ||
| Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms | Q30492587 | ||
| Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons | Q45300079 | ||
| Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. | Q45302980 | ||
| Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice | Q45304684 | ||
| Astrocytes in Huntington's chorea: accomplice or guilty of the neuronal death? | Q45306684 | ||
| Weight loss in early stage of Huntington's disease | Q45307146 | ||
| Synaptic mitochondria are more susceptible to Ca2+overload than nonsynaptic mitochondria | Q46975941 | ||
| Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. | Q52540884 | ||
| Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice | Q33796172 | ||
| Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection | Q34088963 | ||
| Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum | Q34090320 | ||
| Huntington's disease: the challenge for cell biologists | Q34106564 | ||
| Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease | Q34185510 | ||
| Astrocyte mitochondrial mechanisms of ischemic brain injury and neuroprotection | Q35707254 | ||
| Early resistance to cell death and to onset of the mitochondrial permeability transition during hepatocarcinogenesis with 2-acetylaminofluorene | Q35811320 | ||
| Mitochondrial trafficking in neurons: a key variable in neurodegeneration? | Q35891832 | ||
| Astrocytic contributions to bioenergetics of cerebral ischemia | Q36104665 | ||
| Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? | Q36308082 | ||
| 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. | Q36318579 | ||
| Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity | Q36320596 | ||
| Mitochondria and neuronal activity. | Q36648486 | ||
| Mitochondrial trafficking and morphology in healthy and injured neurons | Q36692390 | ||
| Astrocyte metabolism and signaling during brain ischemia | Q36983687 | ||
| Mitochondria modulate Ca2+-dependent glutamate release from rat cortical astrocytes | Q37039965 | ||
| Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view | Q37179623 | ||
| Therapeutic application of histone deacetylase inhibitors for central nervous system disorders | Q37283454 | ||
| Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models | Q37348586 | ||
| Multiple roles of HDAC inhibition in neurodegenerative conditions. | Q37407855 | ||
| The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease | Q37459062 | ||
| Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond | Q37642283 | ||
| Targeting glial cells to elucidate the pathogenesis of Huntington's disease. | Q37682680 | ||
| Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. | Q37733750 | ||
| Techniques to investigate neuronal mitochondrial function and its pharmacological modulation. | Q37833113 | ||
| Mitochondria exert a negative feedback on the propagation of intracellular Ca2+ waves in rat cortical astrocytes | Q39508107 | ||
| Juvenile Huntington chorea: Clinical, ultrastructural, and biochemical studies | Q39838932 | ||
| Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-D-aspartate receptor subunits | Q40150876 | ||
| Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 | ||
| Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. | Q40721588 | ||
| Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. | Q41969689 | ||
| In situ respiration and bioenergetic status of mitochondria in primary cerebellar granule neuronal cultures exposed continuously to glutamate | Q42462301 | ||
| Cyclosporin A increases mitochondrial calcium uptake capacity in cortical astrocytes but not cerebellar granule neurons | Q43247423 | ||
| The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. | Q44378787 | ||
| Glutamate decreases mitochondrial size and movement in primary forebrain neurons. | Q44566043 | ||
| Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells | Q44605170 | ||
| Mitochondrial defect in Huntington's disease caudate nucleus | Q45291734 | ||
| In situ mitochondrial Ca2+ buffering differences of intact neurons and astrocytes from cortex and striatum. | Q45292096 | ||
| P433 | issue | 3 | |
| P921 | main subject | mitochondrion | Q39572 |
| Huntington's disease | Q190564 | ||
| striatum | Q1319792 | ||
| P304 | page(s) | 227-234 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Journal of Bioenergetics and Biomembranes | Q5044470 |
| P1476 | title | Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration | |
| P478 | volume | 42 |
| Q88701768 | A stocked toolbox for understanding the role of astrocytes in disease |
| Q38422519 | Astrocytes in neurodegenerative disease |
| Q90140618 | Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models |
| Q47929663 | Diversity of astroglial responses across human neurodegenerative disorders and brain aging |
| Q26999015 | Metabolic disturbances in diseases with neurological involvement |
| Q28394301 | Metabolism in HD: still a relevant mechanism? |
| Q36124905 | Mitochondria: the next (neurode)generation |
| Q45302844 | Mitochondrial Metabolism in a Large-Animal Model of Huntington Disease: The Hunt for Biomarkers in the Spermatozoa of Presymptomatic Minipigs. |
| Q38021396 | Mitochondrial dynamics: the intersection of form and function |
| Q39014966 | Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime |
| Q38818474 | Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders. |
| Q36411728 | ROCK-phosphorylated vimentin modifies mutant huntingtin aggregation via sequestration of IRBIT. |
| Q90236449 | Sodium selenite protects from 3-nitropropionic acid-induced oxidative stress in cultured primary cortical neurons |
| Q36863901 | Targeting sirtuin-1 in Huntington's disease: rationale and current status |
| Q38035753 | Taurine and central nervous system disorders |
| Q37371488 | Thalamic metabolic abnormalities in patients with Huntington's disease measured by magnetic resonance spectroscopy |
| Q37408287 | The Association of VDAC with Cell Viability of PC12 Model of Huntington's Disease. |
| Q53716390 | Therapy development in Huntington disease: From current strategies to emerging opportunities. |
Search more.